Pathogenesis of Chronic Allograft Dysfunction Progress to Renal Fibrosis

Area of Science:

• Nephrology
• Transplantation Immunology
• Cellular and Molecular Medicine

Background:

• Kidney transplantation is a vital treatment for end-stage renal disease (ESRD).
• Renal allografts frequently suffer acute kidney injury (AKI) and chronic allograft dysfunction (CAD), leading to fibrosis and function loss.
• Understanding the pathogenesis of AKI and CAD is crucial for developing effective interventions.

Purpose of the Study:

• To investigate the roles of immunity, inflammation, and apoptosis in AKI and CAD.
• To explore tubular epithelial cells (TECs) as both victims and mediators in renal injury and repair.
• To evaluate therapeutic strategies targeting TECs and fibroblasts for preventing renal fibrosis.

Main Methods:

• Utilized ischemia-reperfusion injury (IRI) and immunosuppressant-induced AKI models.
• Focused on the cellular mechanisms involving tubular epithelial cells (TECs).
• Assessed the efficacy of siRNA targeting caspase-3 and erythropoietin derivatives (HBSP, CHBP).

Main Results:

• Identified TECs as key players in renal injury, repair, and fibrosis.
• Demonstrated potential therapeutic benefits of targeting TECs and fibroblasts.
• Showcased promising results with siRNA and erythropoietin derivatives in treating AKI and preventing CAD.

Conclusions:

• Targeting TECs alongside fibroblasts is a fundamental strategy for preventing and treating renal fibrosis.
• Novel therapies like siRNA and erythropoietin derivatives offer potential for AKI treatment and CAD prevention.
• Despite advancements, timely diagnosis and precise therapy for AKI and prevention of CAD remain significant challenges in kidney transplantation.